Optimi Health finishes psilocybin batch for Canadian MDD trial and Australian TRD supplySep 23Regulatory decisionOptimi Health Corp.psilocybin
Optimi Health names Michael Blough to lead clinical development for psychedelic trialsSep 22Clinical readoutOptimi Health Corp.
Compass Pathways reports Q2 2026 results, cites Phase 3 data as NDA filing nearsAug 5Quarterly updateCOMPASS Pathwayspsilocybin
Compass Pathways reports 26-week COMP006 data for psilocybin depression treatmentJul 7Clinical readoutCOMPASS Pathwayspsilocybin
Sign inSign in